Short Term
Mean Reversion
Neutral
Trend
Neutral
Event
Neutral
Halo Model
MQV
Very Strong
GARP
Very Strong
MQV Small
Very Strong
Momentum
Price
Weak
Earnings
Strong
Growth
Earnings
Very Strong
Dividends
Very Strong
Quality
Capital Efficiency
Very Strong
Balance Sheet
Very Strong
Telephone
N/A
Address
Suite 12.01, Level 12 4-6 Bligh Street Sydney, New South Wales (NSW) 2000
Description
Imugene Ltd. is a biopharmaceutical company, which engages in the research, development, and commercialization of immunotherapies against cancer. Its products include b-cell peptide cancer vaccines, arginine modulators, and mimotopes. The company was founded on May 30, 1986 and is headquartered in Sydney, Australia.
Market Cap
PE
EV/EBITDA
DIV Yield
Franking
Ex Dividend Date (est.)
52 weeks range
Low 0.04 - 0.15
Trade Value (12mth)
AU$613,006.00
1 week
-9.68%
1 month
12%
YTD
-49.09%
1 year
-12.5%
All time high
0.63
EPS 3 yr Growth
427.50%
EBITDA Margin
N/A
Operating Cashflow
-$97m
Free Cash Flow Return
-63.00%
ROIC
-96.90%
Interest Coverage
-282.40
Quick Ratio
3.90
Shares on Issue (Fully Dilluted)
7274m
HALO Sector
Healthcare
Next Company Report Date
29-Aug-25
Ex Dividend Date (est.)
N/A
Next Dividend Pay Date (est.)
N/A
Reporting Currency
AUD
Short Sell (% of issue)
5.03
Date | Announcements |
---|---|
04 September 24 |
Imugene Azer-cel Webinar Presentation
×
Imugene Azer-cel Webinar Presentation |
04 September 24 |
Application for quotation of securities - IMU
×
Application for quotation of securities - IMU |
04 September 24 |
Cleansing Notice
×
Cleansing Notice |
03 September 24 |
Imugene Webinar - Azer-cel Trial Update
×
Imugene Webinar - Azer-cel Trial Update |
30 August 24 |
Appendix 4E and Annual Report
×
Appendix 4E and Annual Report |
30 August 24 |
Corporate Governance Statement 2024 and Appendix 4G
×
Corporate Governance Statement 2024 and Appendix 4G |
30 August 24 |
Imugene ESG Report 2024
×
Imugene ESG Report 2024 |
02 August 24 |
Release of Shares from Voluntary Escrow
×
Release of Shares from Voluntary Escrow |
31 July 24 |
Quarterly Activities/Appendix 4C Cash Flow Report
×
Quarterly Activities/Appendix 4C Cash Flow Report |
12 July 24 |
Notification regarding unquoted securities - IMU
×
Notification regarding unquoted securities - IMU |
12 July 24 |
Notification of cessation of securities - IMU
×
Notification of cessation of securities - IMU |
10 July 24 |
First patient dosed in Phase 1 bile tract cancer trial
×
First patient dosed in Phase 1 bile tract cancer trial |
08 July 24 |
Application for quotation of securities - IMU
×
Application for quotation of securities - IMU |
08 July 24 |
Change of Director's Interest Notice x6
×
Change of Director's Interest Notice x6 |
04 July 24 |
Imugene Corporate Presentation
×
Imugene Corporate Presentation |
24 June 24 |
Imugene onCARlytics Doses First Patient in IV Combination
×
Imugene onCARlytics Doses First Patient in IV Combination |
30 May 24 |
Imugene Presentation to Bell Potter Conference
×
Imugene Presentation to Bell Potter Conference |
06 May 24 |
Application for quotation of securities - IMU
×
Application for quotation of securities - IMU |
30 April 24 |
Quarterly Activities/Appendix 4C Cash Flow Report
×
Quarterly Activities/Appendix 4C Cash Flow Report |
23 April 24 |
Change of Director's Interest Notice - PH
×
Change of Director's Interest Notice - PH |
19 April 24 |
Notification regarding unquoted securities - IMU
×
Notification regarding unquoted securities - IMU |
17 April 24 |
Imugene & Kincell Bio Strategic Partnership Investor Webinar
×
Imugene & Kincell Bio Strategic Partnership Investor Webinar |
16 April 24 |
Imugene and Kincell Bio Announce Strategic Partnership
×
Imugene and Kincell Bio Announce Strategic Partnership |
15 April 24 |
Bile Tract Cancer Study Opens after MAST High Dose Clearance
×
Bile Tract Cancer Study Opens after MAST High Dose Clearance |
15 April 24 |
Notification regarding unquoted securities - IMU
×
Notification regarding unquoted securities - IMU |
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Percent of Issue
Value ($M)
Prior Change
7 Day Change
1 Month Change
3 Month Change
Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.
Unlock true investor intelligence
Research, trade and manage global markets from one place with HALO Global. It’s trading - the way you want it.
Get the latest insights and hot tips delivered right to your inbox
HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.